Search

NIH WNV Monoclonal Antibodies Available for Licensing

NIAID, a component of the NIH, is making five novel neutralizing human monoclonal antibodies targeting West Nile virus (WNV) available for commercial licensing under 35 U.S.C. 209 and 37 CFR Part 404. The antibodies, which bind the WNV envelope protein, are in pre-clinical stage and are available alone or in combination, with accompanying nucleic acids, vectors, and host cells for production. HHS Reference No. E-200-2024-0 covers U.S. Provisional Patent Application (filed July 31, 2024) and PCT Application No. PCT/US2025/039922 (filed July 30, 2025).

PRC Notices USPS Competitive Product List Filings for Comment

The Postal Regulatory Commission published a notice on April 22, 2026, informing the public of USPS filings to add competitive negotiated service agreements to the Competitive product list. Two dockets are noticed: MC2026-209/K2026-208 (Priority Mail Express International, Priority Mail International & First-Class Package International Service Contract 111) and MC2026-216/K2026-214 (Fulfillment Standardized Distinct Product PM-GA Contract 966). Comments on the public proceeding are due April 27, 2026.

NIH/NIAID Offers West Nile Virus Neutralizing Antibodies for Licensing

NIAID announces availability for licensing of seven new fully human monoclonal antibodies (AIS-196, AIS-204, AIS-259, AIS-260, AIS-261, AIS-262, and AIS-265) that neutralize West Nile virus by targeting its envelope protein. The antibodies demonstrated strong virus-blocking activity in laboratory studies and protective effects in mouse models. Licensing inquiries should directed to Brian Bailey at 240-669-5128 or bbailey@mail.nih.gov, referencing HHS Reference No. E-021-2026-0.